FDA Recommends Against Initiating Olaratumab in Patients With Advanced Soft Tissue Sarcoma

FDA issued a statement recommending against the use of olaratumab in new patients with sarcoma following the release of negative results from the phase 3 ANNOUNCE trial.

from Latest articles from Cancer Therapy Advisor News http://bit.ly/2B91vW2